胸腺瘤上皮生长因子受体的表达及其临床意义

目的　研究上皮生长因子受体 (EGFR)在胸腺瘤中的表达水平及其与临床病理关系。方法　应用SABC免疫细胞化学方法检测EGFR在 6 2例胸腺瘤组织和 8例正常胸腺组织中的表达程度。结果　EGFR在胸腺瘤中的表达率及染色强度均显著高于正常胸腺组织 (P <0 .0 1) ;EGFR随着胸腺瘤Masaoka分期进展而染色强度呈增高趋势 ;在合并严重的重症肌无力(MG)的胸腺瘤中EGFR的染色程度明显增强。结论　EGFR与胸腺瘤及重症肌无力的发生、发展有一定的内在联系 ,EGFR高表达者 ,肿瘤的侵袭性强 ,出现严重的MG的几率高 ,预后不理想 ,需加强术后治疗和随访。

Expression of EGFR in thymoma and its clininical significance

Objective To investigate the expression level of EGFR in thymoma and its pathological and clinical correlation. Methods The expression of EGFR was studied in 62 cases of thymoma and 8 cases of normal thymus tissue through immunohistochemistry. Results The expression rate and intensity were significantly higher in thymoma than those in normal tissue(P< 0.01); The expression intensity in thymoma showed a tendency to increase as the Masaoka stage advances;The EGFR expression intensity was significantly stronger in thymoma with severe MG. Conclusion The expression of EGFR can be linked to the generation and progression of thymoma and MG that is the higher the expression level of EGFR the more invasive the tumor is and the more likely severe MG develops. As the prognosis is poor in these cases it is important to strengthen postoperative treatment and follow up.